Physician profile
Christopher Starr
NPI 1720076185
$294,227.42
in general payments reported to CMS, 2019-2025
28 companies · $49K in 2025
The $49K reported for 2025 was more than what 98% of Cornea and External Diseases Specialist providers received nationally (typical 2025 total: $477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37K · 2020: $111K · 2021: $32K · 2022: $17K · 2023: $9,903 · 2024: $39K · 2025: $49K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $89K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,600 · Food and Beverage: $2,381 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,250 · Travel and Lodging: $97.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $88,756.25 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,600.00 |
| Food and Beverage | $2,381.29 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,250.00 |
| Travel and Lodging | $97.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $39,462.19 | 2022-2025 | Xiidra, Miebo, Prolensa |
| Novartis Pharmaceuticals Corporation | $37,159.20 | 2019-2022 | |
| Allergan, INC. | $36,772.72 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $36,603.37 | 2019-2021 | |
| Abbvie INC. | $35,800.12 | 2023-2025 | Vuity, Lumigan |
| Kala Pharmaceuticals, INC. | $32,311.50 | 2019-2022 | |
| Dompe US, INC. | $22,764.40 | 2019-2024 | Oxervate |
| Tearlab Corp | $11,412.27 | 2019-2024 | Tearlab Osmolarity System, Scoutpro Osmolarity System |
| Tarsus Pharmaceuticals, INC. | $8,750.00 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $6,508.10 | 2019-2025 | |
| Alcon Research LLC | $5,500.00 | 2024-2025 | Tryptyr |
| Quidel Corporation | $4,601.51 | 2019-2022 | |
| Sight Sciences, INC. | $3,902.42 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument, Tearcare System |
| Eyevance Pharmaceuticals LLC | $2,992.08 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $2,267.66 | 2020-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,062.56 | 2024 | Tepezza |
| Aerie Pharmaceuticals, INC. | $1,600.00 | 2021 | |
| Oyster Point Pharma, INC. | $1,452.83 | 2022 | |
| Glaukos Corporation | $1,125.00 | 2024 | Ce-Marked Kxla System |
| Rxsight INC | $234.37 | 2021-2023 | Rxsight Contact Lens, Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Cartridge |
| Eyepoint US, INC. | $232.06 | 2019-2020 | |
| Ivantis, INC | $190.04 | 2019 | |
| Beaver-Visitec International, INC. | $149.01 | 2023 | |
| Omeros Corporation | $125.00 | 2019 | |
| Ocular Therapeutix, INC. | $84.57 | 2019-2024 | Dextenza |
| Biotissue Holdings INC. | $84.40 | 2023 | |
| Harrow Eye, LLC | $56.67 | 2025 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $23.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Starr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.